Literature DB >> 27591501

Dermatofibrosarcoma Protuberans: Wide Local Excision Versus Mohs Micrographic Surgery.

John T Mullen1.   

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a rare dermal soft tissue sarcoma characterized by a typically indolent clinical course. The greatest clinical challenge in management of DFSP is achieving local control. There is vigorous debate in the literature as to the optimal surgical approach to these tumors. The choice between wide local excision and Mohs micrographic surgery for DFSP should be governed by the attainment of three goals: (1) to completely excise the tumor with negative margins, tantamount to cure; (2) to preserve function, optimize cosmesis, and minimize morbidity of resection; and (3) to minimize cost and inconvenience to the patient and the health care system at large.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cutaneous sarcoma; Dermatofibrosarcoma protuberans; Mohs surgery; Recurrence; Wide local excision

Mesh:

Year:  2016        PMID: 27591501     DOI: 10.1016/j.soc.2016.05.011

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  4 in total

Review 1.  Dermatofibrosarcoma Protuberans.

Authors:  Alvaro E Acosta; Catalina Santa Vélez
Journal:  Curr Treat Options Oncol       Date:  2017-08-10

2.  Mohs Micrographic Surgery for Dermatofibrosarcoma Protuberans in 15 Patients: The University of Arkansas for Medical Sciences Experience.

Authors:  Blake St Clair; Abigale Clark; Benjamin Rollins; Thomas A Jennings
Journal:  Cureus       Date:  2022-04-14

3.  Collagen Features of Dermatofibrosarcoma Protuberans Skin Base on Multiphoton Microscopy.

Authors:  Shulian Wu; Yudian Huang; Zhifang Li; Huaqing Wu; Hui Li
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

Review 4.  A Rare Malignant Disease, Dermatofibrosarcoma Protuberans of the Breast: A Retrospective Analysis and Review of Literature.

Authors:  Yihua Wang; Yu Wang; Rui Chen; Zhenrong Tang; Shengchun Liu
Journal:  Biomed Res Int       Date:  2020-11-09       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.